S2E5: Decoding the Risk: What New Cholesterol Guidelines Mean for Women with Dr. Harpreet Tsui

Welcome to Clearly Hormonal
(formerly Reset Recharge)

S2 E5
The number-one cause of death in women is still heart disease — and perimenopause is where your cardiovascular risk starts to quietly climb. This week, Dr. Komal sits down with Dr. Harpreet Tsui, an internist, obesity medicine specialist, and founder of Coronado Health (a direct primary care practice in Nevada), to break down the 2026 ACC/AHA Dyslipidemia Guidelines — the biggest update to cholesterol guidelines in years.
This is a personal episode. Both physicians are Southeast Asian women with significant family histories of heart disease. Both are managing their own cardiometabolic health in real time. And neither of them is willing to accept "your numbers look fine" as the end of the conversation.
They cover what's changed in the guidelines, which genetic cholesterol markers your doctor may not be ordering, why perimenopause can flip your lipid panel overnight, and the exact language to use at your next appointment to get the full picture.

Decoding the Risk: What the New Cholesterol Guidelines Mean for Women — with Dr. Harpreet Tsui

By Dr. Komal Patil-Sisodia, MD | Eastside Menopause & Metabolism

If you've ever walked out of a doctor's appointment with a "your cholesterol looks fine" and a vague sense that something important wasn't said — this episode is for you.

On this week's episode of Clearly Hormonal, I sat down with Dr. Harpreet Tsui, an internist, obesity medicine specialist, and founder of Coronado Health, a direct primary care practice in Nevada. Harpreet and I go way back — we're both Southeast Asian women, both physicians who have navigated our own health scares, both daughters who watched our mothers' heart disease get missed or dismissed for years. This conversation was personal. It was also one of the most clinically important ones I've had on this podcast.

We talked about the 2026 ACC/AHA Dyslipidemia Guidelines — the biggest update to cholesterol guidelines in years — and what they actually mean for women, especially those of us in midlife.

Why the Old "Your Numbers Look Fine" Doesn't Cut It Anymore

For a long time, cholesterol management was pretty simple on the surface: check your LDL, compare it to a cutoff, prescribe a statin if it was too high. Easy. Except it missed a lot of people — including a lot of women.

The new guidelines move away from chasing a single number and toward a risk-based approach. That means using the updated PREVENT ASCVD calculator, which factors in not just your cholesterol panel, but your family history, ethnicity, triglycerides, HDL, and even your ZIP code (a nod to the role social determinants of health play in your cardiovascular risk). It gives you a 10-year and 30-year cardiovascular risk estimate — not just a snapshot of today, but a picture of where you're headed.

This is a fundamental shift: we're not treating your labs, we're treating your life trajectory.

The Genetic Cholesterol Markers Your Doctor Might Not Be Checking

Here's something that came up in our conversation that I feel strongly about: your standard lipid panel — total cholesterol, LDL, HDL, triglycerides — can look completely normal while your actual cardiovascular risk is quietly elevated.

The new guidelines now call out two genetic cholesterol particles as independent cardiac risk factors:

Lipoprotein(a) — also called Lp(a): Lp(a) is largely determined by genetics and doesn't respond much to diet or lifestyle. The guidelines recommend checking it at least once in a lifetime. Harpreet and I both push for checking it again in perimenopause and post-menopause, because it can change. Mine did — it was normal before perimenopause, and then it wasn't. That's not a coincidence.

Apolipoprotein B — ApoB: ApoB is a better marker of cardiovascular risk than LDL-C alone, especially in people with insulin resistance, diabetes, or metabolic syndrome. I've seen patients with completely normal LDLs and elevated ApoBs. If we weren't checking both, we'd miss it entirely.

If you haven't had these checked — ask. These aren't exotic tests. They're just underutilized ones.

Female-Specific Risk Factors Are Finally in the Guidelines

This was the section of the new guidelines that made Harpreet and me both feel seen and simultaneously a little alarmed about our own health history.

The 2026 guidelines formally recognize the following as independent cardiovascular risk factors in women:

Menopause and perimenopause — when estrogen declines, LDL rises, HDL patterns shift, and visceral fat increases, creating a cascade of insulin resistance and inflammation
Polycystic Ovarian Syndrome (PCOS) — associated with lifetime increased risk of diabetes, metabolic syndrome, hypertension, and heart disease; not just a reproductive diagnosis
Gestational diabetes — even if your blood sugar normalized after delivery, you carry a higher risk of developing diabetes and cardiovascular disease; that missed three-month postpartum glucose tolerance test matters more than most people know
Preeclampsia and gestational hypertension — a history of either significantly elevates your long-term cardiovascular risk

These aren't obscure edge cases. These are extremely common experiences that have been chronically under-weighted in risk conversations with women. The fact that they're now embedded in major guidelines is genuinely meaningful — both for what it means for clinical conversations and for women advocating for themselves.

The Estrogen-Cholesterol Connection Nobody Explained to You

One of the most important things we discussed: why does your cholesterol change so dramatically in perimenopause, even when nothing about your lifestyle has changed?

Here's the short version: estrogen plays a role in how your body processes and stores fat. When estrogen declines, your body composition shifts — you hold onto less muscle and gain more fat, particularly visceral fat around the abdomen. Visceral fat drives insulin resistance. Insulin resistance alters how your body clears LDL and other lipid particles from the bloodstream. The result? Cholesterol goes up, inflammation goes up, and your cardiometabolic risk profile changes — sometimes overnight.

Harpreet's LDL went from 77 to 177 in perimenopause. Her lifestyle had actually gotten better. Mine did something similar with Lp(a). Neither of us did anything wrong. Our estrogen dropped, and our lipids followed.

This is why I'm checking cardiometabolic markers on every midlife woman who walks into my practice — before anything on the standard panel looks alarming.

Lower LDL Targets, More Tools, and Why Statins Deserve a Fair Trial

The updated guidelines set lower LDL targets for higher-risk patients:

High risk: LDL target below 70 mg/dL
Very high risk: LDL target below 55 mg/dL

These feel aggressive compared to where we've been, but the data supports them. Lower LDL means less plaque, less inflammation, less risk. Harpreet described attending a conference pre-pandemic where vascular specialists were pushing for LDL targets at or below 50 — the guidelines are finally catching up to what some of the most experienced clinicians have known for years.

On statins — because this conversation came up, and it always does: Harpreet shared that she prescribed herself a statin and then left the bottle sitting on her nightstand for two weeks before she actually took it. A physician. Who prescribed it to herself. Still hesitated. Because even doctors absorb the noise. But statins aren't just cholesterol-lowering drugs. They're anti-inflammatory. There's no plant sterol or omega-3 supplement that replicates that mechanism. If you've had concerns about statins, have a real conversation with your doctor — not a Google rabbit hole conversation, a real one.

And if you genuinely don't tolerate statins? The guidelines support PCSK9 inhibitors as an alternative. They're injectable, better tolerated, and highly effective. They've been expensive and hard to access, but that's changing. There are also medications in the pipeline specifically targeting Lp(a). The toolkit is expanding.

What to Actually Ask at Your Next Appointment

Both Harpreet and I got specific about this, because "talk to your doctor" is only useful advice if you know what to say:

Know your family history. Dig into it. Ask your relatives. When did people have heart attacks, strokes, or get diagnosed with high cholesterol? How old were they? Bring that to your appointment.
Ask for the PREVENT ASCVD calculator. Ask your doctor to run your 10-year and 30-year cardiovascular risk. You deserve to see the full picture, not just today's numbers.
Request Lp(a) and ApoB. Especially if you're in perimenopause, have a family history of early heart disease, have diabetes or insulin resistance, or are South Asian (or have another ethnic background with elevated baseline risk).
Ask about your insulin level. It's not on a standard metabolic panel, but it tells a story — especially for women with PCOS or those who had gestational diabetes.
Ask about a coronary artery calcium (CAC) score. Harpreet discovered hers was 214 at age 43 — with a "perfect" LDL. It changed her entire management plan. You cannot see calcium buildup in your arteries on a standard lipid panel.
Ask about your hsCRP. This is a marker of cardiovascular inflammation, and it matters — especially in midlife when visceral fat is driving inflammation even if your BMI looks acceptable.

A Note on Mistrust, Medicine, and Changing Guidelines

We spent some time in this episode talking about something that doesn't get discussed enough: why guidelines change, and why that's not a reason to distrust medicine. It's the whole point of medicine.

We've all been burned by advice that shifted. We've all felt the frustration of being told one thing and then another. But the reason lipid guidelines have changed is because we've done more research, followed more patients for longer, and built better tools. The guidelines today are better than the guidelines from 2001 not because doctors were lying to you then, but because we know more now.

That's also why Harpreet and I both stay humble about our own bodies. Harpreet prescribed herself a statin and left it on her nightstand for two weeks before she took it. I've gone down my own supplement rabbit holes. We've both had moments where we had to look in the mirror and ask: what would I tell my patient?

Our genetics don't care how well we eat. They don't care how much we exercise or how good our intentions are. Sometimes the most evidence-based thing you can do is take the medication.

Final Thoughts

My mom's heart disease was missed for two years in the 1990s. She was a 40-year-old woman, short of breath, and everyone thought it was her lungs — because "why would a 40-year-old woman have a heart attack?" By the time they found it, she needed open-heart surgery.

Here we are, almost 30 years later, and we finally have guidelines that see women. That see our hormones, our pregnancies, our genetics, and our perimenopause as relevant to our hearts — not just our reproductive systems.

If you take nothing else from this episode: you are not overreacting. You are not being dramatic. Your midlife body is genuinely changing, and those changes have cardiovascular consequences that deserve to be monitored, understood, and treated.

You now know the language. Use it at your next appointment.

Listen to this episode wherever you get your podcasts, or find it at eastsidemm.com/podcast.

Follow Dr. Harpreet Tsui: @drharpreet.tsu i on Instagram and TikTok | coronadohealthdpc.com

Follow Dr. Komal Patil-Sisodia: @drpatilsis odia on Instagra m and TikTok

This content is for educational purposes only and does not constitute personalized medical advice. Please discuss your specific health concerns with your own healthcare provider.

Dr. Komal Patil-Sisodia is a triple board-certified physician (Internal Medicine, Endocrinology, Obesity Medicine) and Menopause Society Certified Practitioner. She is the founder of Eastside Menopause & Metabolism and host of the Clearly Hormonal podcast.